YD Bio (NASDAQ:YDES) Raised to Hold at Wall Street Zen

YD Bio (NASDAQ:YDES) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of YD Bio in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, YD Bio currently has a consensus rating of “Sell”.

YD Bio Trading Down 5.0%

Shares of YD Bio stock opened at $8.58 on Friday. YD Bio has a 12-month low of $7.20 and a 12-month high of $25.00. The firm’s fifty day moving average is $11.05.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in YD Bio stock. Geode Capital Management LLC boosted its holdings in YD Bio Limited (NASDAQ:YDES) by 10.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 58,363 shares of the biotechnology company’s stock after acquiring an additional 5,292 shares during the quarter. Geode Capital Management LLC owned 0.08% of YD Bio worth $711,000 at the end of the most recent quarter.

About YD Bio

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.